Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Comparison of a Silicone Hydrogel Daily Disposable Multifocal Contact Lens to a Marketed Product

Lead Sponsor:

Johnson & Johnson Vision Care, Inc.

Conditions:

Visual Acuity

Eligibility:

All Genders

40-70 years

Phase:

NA

Brief Summary

This is a single-masked, 2×3 crossover, randomized-controlled, dispensing clinical trial to evaluate overall quality of vision.

Eligibility Criteria

Inclusion

  • Potential subjects must satisfy all of the following criteria to be enrolled in the study
  • Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • Appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • Be at least 40 years of age and not greater than 70 years of age at the time of consent.
  • Own a wearable pair of spectacles if required for their distance vision.
  • Be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 6 hours per wear day, for 1 month or more duration).
  • Either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire" (Appendix D).
  • The subject's distance spherical equivalent refraction (vertex corrected if ≥-4.25 D) must be in the range of -1.25 D to -5.75 D or +0.75 D to +3.25 D in each eye.
  • The subject's refractive cylinder must be ≤0.75 D in each eye.
  • The subject's ADD power must be in the range of +0.75 D to +2.50 D.
  • The subject must have distance best corrected visual acuity of 20/20-3 or better in each eye.

Exclusion

  • Potential subjects who meet any of the following criteria will be excluded from participating in the study:
  • The subject must not:
  • Be currently pregnant or lactating.
  • Have any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
  • Have any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
  • Have any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, dacryocystorhinostomy, peripheral iridotomy/iridectomy, cataract surgery, retinal surgery, etc.).
  • Have a history of amblyopia, strabismus or binocular vision abnormality.
  • Use of any of the following medications within 1 week prior to enrollment: oral retinoid, oral tetracyclines, anticholinergics, oral phenothiazines, oral/inhaled corticosteroids. See section 9.1 for further examples.
  • Use of any ocular medication, with the exception of rewetting drops.
  • Have a history of herpetic keratitis.
  • Have a history of irregular cornea.
  • Have a history of pathological dry eye.
  • Have Participated in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
  • Be an employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
  • Have any known hypersensitivity or allergic reaction to non-preserved rewetting drop solutions or sodium fluorescein.
  • Have clinically significant (Grade 2 or greater) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.
  • Have any current ocular infection or inflammation.
  • Have any current ocular abnormality that may interfere with contact lens wear.

Key Trial Info

Start Date :

February 18 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 29 2022

Estimated Enrollment :

143 Patients enrolled

Trial Details

Trial ID

NCT05258149

Start Date

February 18 2022

End Date

April 29 2022

Last Update

May 19 2023

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Vue Optical Boutique

Jacksonville, Florida, United States, 32205

2

Stam & Associates Eye Care

Jacksonville, Florida, United States, 32256

3

Sabal Eye Care

Longwood, Florida, United States, 32779

4

Maitland Vision Center

Maitland, Florida, United States, 32751